Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBT Margin (2016 - 2025)

Historic EBT Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to 803.05%.

  • Agios Pharmaceuticals' EBT Margin fell 119703300.0% to 803.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 919.64%, marking a year-over-year decrease of 31228500.0%. This contributed to the annual value of 1967.15% for FY2024, which is 32797800.0% up from last year.
  • Agios Pharmaceuticals' EBT Margin amounted to 803.05% in Q3 2025, which was down 119703300.0% from 903.6% recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' EBT Margin ranged from a high of 11167.28% in Q3 2024 and a low of 12073.44% during Q1 2022
  • For the 4-year period, Agios Pharmaceuticals' EBT Margin averaged around 1230.76%, with its median value being 1234.27% (2023).
  • As far as peak fluctuations go, Agios Pharmaceuticals' EBT Margin surged by 124015600bps in 2024, and later crashed by -119703300bps in 2025.
  • Agios Pharmaceuticals' EBT Margin (Quarter) stood at 2150.44% in 2022, then skyrocketed by 37bps to 1350.7% in 2023, then increased by 27bps to 982.28% in 2024, then grew by 18bps to 803.05% in 2025.
  • Its last three reported values are 803.05% in Q3 2025, 903.6% for Q2 2025, and 1037.61% during Q1 2025.